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Background: Patients having cardiac operations often require blood transfu- 
sions. Aprotinin reduces the need for blood transfusions during coronary 
artery bypass graft operations. To determine the safety and effectiveness of 
aprotinin in reducing the use of allogeneic blood and postoperative mediastinal 
chest tube drainage, we studied 212 patients undergoing primary sternotomy 
for valve replacement or repair. Methods: This study was multicenter, random- 
ized, prospective, double-blind, and placebo-controlled. Patients received high- 
dose aprotinin (n = 71), low-dose aprotinin (n = 70), or placebo (n = 71). The 
study medication was given as a loading dose followed by a continuous infusion 
and pump prime dose. Heparin administration was standardized. Transfu- 
sions, postoperative mediastinal shed blood, and adverse events were tracked. 
Results: Demographic profiles were similar among the treatment groups. 
Aprotinin did not decrease the percentage of patients receiving transfusions 
when compared with placebo (high-dose aprotinin, 63%, p = 0.092; low-dose 
aprotinin, 52%, p = 0.592; placebo, 48%). Aprotinin was associated with a 
reduction in the volume of mediastinal shed blood (high-dose aprotinin vs 
placebo, p = 0.002; low-dose aprotinin vs placebo, p = 0.017). Adverse events 
were equally distributed among the treatment groups except for postoperative 
renal dysfunction (high-dose aprotinin, 11%; low-dose aprotinin, 7%; placebo, 
0%; p = 0.01). A disproportionate number of patients in the high-dose 
aprotinin group with postoperative renal dysfunction also had diabetes melli. 
tus. Conclusions: Aprotinin treatment in this population did not reduce 
allogeneic blood use, although there were significant reductions in the volume 
of mediastinal shed blood. (J Thorac Cardiovasc Surg 1996;112:1081-9) 
C ardiac operations necessitating extracorporeal circulation often are associated with the use of 
allogeneic blood for the treatment of bleeding or to 
counter the effects of hemodilution. 1 Exposure to 
allogeneic blood has decreased over the past 10 
From the Departments of Anesthesia and Surgery, Massachusetts 
General Hospital, Boston, Mass.; the Department of Surgery, 
University of Alabama, Birmingham, Ala.; Miles Inc., West 
Haven, Conn.; the Departments of Anesthesia nd Surgery, 
Brigham and Women's Hospital, Boston, Mass.; the Depart- 
ment of Surgery, The Cleveland Clinic Foundation, Cleve- 
land, Ohio; and the Department of Anesthesia; Emory Uni- 
versity Hospital, Atlanta, Ga. 
Research supported in part by grants from Miles Inc., West 
Haven, Conn., and Rowland Foundation, Cambridge, Mass.
Received for publication Oct.19, 1995; revisions requested Dec. 
26, 1995; revisions received May 3, 1996; accepted for publi- 
cation May 6, 1996. 
Address for reprints: Michael N. D'Ambra, MD, Cardiac Anes- 
thesia Group, Massachusetts General Hospital, Boston, MA 
02114-2696. 
Copyright © 1996 by Mosby-Year Book, Inc. 
0022-5223/96 $5.00 + 0 12/1/74706 
years with the appearance of cell salvaging and 
reinfusion techniques, a better understanding of the 
limits of anemia, and expansion of predonation 
autologous blood programs. 2 Despite these ad- 
vances, patients continue to be exposed to alloge- 
neic blood. In a study by Hardy and associates 2 that 
included 158 patients undergoing primary opera- 
tions for valve repair, patients received transfusions 
of 3.0 + 2.7 units (mean _+ standard deviation) of 
packed red blood cells during their hospitalizations. 
Until recently, most pharmacologic means of reduc- 
ing postoperative bleeding after cardiac operations 
produced mixed resultsJ' 3-s 
Aprotinin, a serine protease inhibitor with potent 
inhibitory effects on kallikrein and plasmin, is a single- 
chain polypeptide consisting of 58 amino acid residues 
and three disulfide bridges, with a molecular weight of 
6512 daltons. Aprotinin was identified in 1930 by 
Kraut and colleagues as a kallikrein inactivator in 
bovine lymph nodes and in 1936 by Kunitz and 
Northrop as a trypsin inhibitor in the bovine pancreas. 6 
The activity of aprotinin is expressed in kallikrein 
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inactivator units (KIU), with one K IU  defined as that 
amount of aprotinin that decreases the activity of two 
biologic kallikrein units by 50%. One milligram of 
aprotinin is equivalent to 7143 KIU. 
In 1987 Royston and associates 7 reported a 
significant reduction in the postoperative mediastinal 
blood loss and in the use of blood transfusions when 
aprotinin was administered prophylactically topatients 
requiring cardiopulmonary bypass. Before that time 
the therapeutic uses for aprotinin were based on its 
ability to inhibit trypsin, plasmin, and tissue kallikrein 
and included acute pancreatitis, hock syndromes, and 
hyperfibrinolytic hemorrhage. TM 
A whole-body inflammatory response is seen when 
the blood contacts foreign surfaces during cardiopul- 
monary bypass. 12 This stress response is mediated in 
part by activation of kallikrein and plasminJ 3 Aproti- 
nin inhibits kallikrein and plasmin in concentrations of
200 KIU/ml and 50 KIU/ml, respectively, and may 
attenuate the deleterious effects of the stress response 
by multiple mechanisms. 13The purpose of the current 
dose-response study was to determine whether apro- 
tinin therapy could safely and effectively reduce expo- 
sure to allogeneic blood in patients undergoing pri- 
mary sternotomy for valve replacement or repair. A 
kallikrein-inhibiting dose, the high-dose aprotinin 
group, and a nonkallikrein-inhibiting dose, the low- 
dose aprotinin group, were included to investigate the 
blood-sparing effect of aprotinin. 
Methods 
Study design. This was a multicenter, andomized, dou- 
ble-blind, placebo-controlled, parallel-group study con- 
ducted at five sites (23 surgeons). Written informed 
consent was obtained from all patients according to the 
guidelines of each hospital's institutional review board. 
Patients who qualified for study entry were randomized to 
receive aprotinin, in one of two doses, or placebo. 
A separate random code, using blocks of six, was gener- 
ated for each site by the statistical department of Bayer Inc. 
(SAS software, SAS Institute, Inc., Cary, N.C.). Double- 
blind conditions were maintained throughout the study. 
Patient selection and demographics. Any patient with a 
primary diagnosis of valvular heart disease who met all of 
the inclusion criteria and none of the exclusion criteria 
were eligible to enter the study. The inclusion criteria 
included primary aortic and/or mitral valve replacement or
repair through a median sternotomy. The patients included 
both men and women who were 18 years of age or older. 
Patients were not eligible for participation if they had a 
known or suspected allergy to aprotinin, a history of 
bleeding diathesis or known coagulation factor deficiency 
that would require prophylactic use of drugs to improve 
hemostasis, were scheduled to undergo a concurrent 
coronary artery bypass graft operation or other cardiac 
operation, were participants in any other investigational 
drug trial, or refused allogeneic blood transfusion therapy. 
A total of 213 patients were enrolled and randomized at 
five sites (site 1 --- 43 patients; site 2 -- 43 patients; site 3 = 
44 patients; site 4 = 40 patients; and site 5 = 42 patients). 
A total of 212 patients received study medication and 
were included in the safety analysis (high-dose aprotinin, 
n = 71; low-dose aprotinin, n = 70; placebo, n = 71). Of 
these 212 patients, 191 were included in the primary 
analysis of efficacy (high-dose aprotinin, n = 65; low-dose 
aprotinin, n = 62; placebo, n = 64). 
Study medication. A preinfusion test dose of study 
medication was administered after induction of anesthe- 
sia. If no untoward effects of the study medication were 
noted, an intravenous loading dose (280 mg aprotinin or 
2 × 10 6 KIU aprotinin = high-dose aprotinin; 140 mg 
aprotinin or 1 × 106 KIU aprotinin = low-dose aprotinin; 
normal saline solution = placebo) was infused over 20 to 
30 minutes • followed by a continuous infusion (70 mg or 
500,000 KIU/hr aprotinin = high-dose aprotinin; 35 mg or 
250,000 KIU/hr aprotinin = low-dose aprotinin; normal 
saline solution = placebo), which was infused until chest 
closure. An additional dose of aprotinin or placebo, 
equivalent o the loading dose, was added to the pump 
prime. 
Aprotinin was supplied by Bayer Inc. (West Haven, 
Conn.) in a concentration of 1.4 mg/ml (10,000 KIU/ml) in 
0.9% sodium chloride solution, without additives or pre- 
servative substances. The placebo (0.9% sodium chloride 
solution) was also provided by Bayer Inc. The high-dose 
aprotinin regimen used in this study was the "Hammer- 
smith regimen," as described by Royston. 13 The study 
medication for each patient was supplied in a Case pack 
containing 14 vials. The loading dose vials, pump prime 
vials, and constant infusion vials were separately identified 
and packaged within the pack for each patient. Investiga- 
tors were blinded to the identity and lot number of each 
case pack. 
Procedures. Anesthesia, conduct of  cardiopulmonary 
bypass, the operation, and postoperative intensive care 
procedures were those routinely practiced at each s ttidy 
center, including monitoring of the activated clotting.time 
with either kaolin or celite activation. Because of the 
interference of aprotinin with celite activation, heparin 
anticoagulation was standardized to either a bolus of 
heparin of 300 U/kg or more with a subsequent heparin 
dose of 150 U/kg 90 minutes later if the patient was still on 
cardiopulmonary bypass or as predicted by a heparin 
dose-response t stJ 4 
Blood conservation measures included the reinfusion of 
residual blood from the cardiotomy reservoir and in 79% 
of the patients the reinfusion of postoperative mediastinal 
shed blood. Efforts to standardize the use of allogeneic 
blood were established. During cardiopulmonary b pass, 
packed red blood cells were administered if the hemato- 
crit value fell below 18%; after the operation, packed red 
blood cells were given if the hematocrit value was less than 
21%. Patients who had donated their own blood before 
the operation received this blood after the operation. 
Blood products were administered when the patient's 
clinical condition necessitated transfusion. Epsilon-ami- 
nocaproic acid and desmopressin were used prophylacti- 
cally only to treat active bleeding after heparin reversal, 
and their use was documented. 
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Study end points. The effectiveness of aprotinin was 
assessed by the percentage of patients requiring any 
allogeneic blood transfusions and by the number of units 
of allogeneic blood required per patient. The use of 
allogeneic blood including the use of whole blood, packed 
red blood cells, fresh frozen plasma, platelets, and cryo- 
precipitate were tracked according to the time when they 
were administered: uring the operation, during the first 
24 hours after the operation, and from postoperative day 
2 through hospital discharge. The ability of aprotinin to 
reduce postoperative mediastinal chest tube drainage was 
assessed through the volume of shed blood during the first 
12 hours after transfer to the intensive care unit and for 
the interval from 12 to 24 hours or until the thoracic 
drains were removed. The frequency of and reason for 
reoperation for bleeding were tracked. 
Patients who could not be evaluated for efficacy. Ex- 
cluded from the efficacy analysis were the following cate- 
gories of patients: patients who did not receive the full 
dose of study medication (n = 3); patients who died within 
the first 6 hours after the operation (n = 1); patients who 
required reexploration for excessive bleeding from an 
anatomically localized site (n = 7); patients who had 
myocardial dysfunction ecessitating intraaortic balloon 
counterpulsation at the end of the operation (n = 1); 
patients who had major bleeding after the operation from 
sites unrelated to the surgical procedure (n = 2); patients 
who received allogeneic blood products in the prime of 
the cardiopulmonary b pass circuit or before the opera- 
tion after the sample for the preoperative complete blood 
count was drawn (n = 4); patients who got study medica- 
tion but did not then have a cardiac operation with 
cardiopulmonary b pass (n = 2); and patients who had a 
prior median sternotomy (n = 1). All patients were 
included in the safety analysis. 
Statistical methods. In the design of the study it was 
estimated that 60% of patients given placebo would 
require allogeneic blood. It was specified that a 50% 
reduction would be considered clinically meaningful. Sam- 
ple size calculations determined that with 65 patients per 
treatment group using a two-tailed test with an c~ level of 
0.05, one would have more than 90% power of detecting 
a difference between the high-dose aprotinin group and 
placebo. All statistical tests were performed with SAS 
Institute statistical software. 
All statistical tests were two-tailed and were performed 
with an c~ level of 0.05. The primary efficacy variable was 
the percentage of patients requiring any allogeneic blood 
transfusions. The secondary efficacy variable was the 
number of units of allogeneic blood required per patient. 
Intent-to-treat analyses were performed on all patients 
given study medication who had operations involving 
cardiopulmonary b pass, The primary comparison i each 
analysis was that of high-dose aprotinin versus placebo. 
Pairwise comparisons of low-dose aprotinin versus pla- 
cebo and high-dose aprotinin versus low-dose aprotinin 
were also performed. The primary efficacy variable and 
categoric variables other than treatment emergency ad- 
verse event rates and incidence rates of laboratory abnor- 
malities were analyzed by means of the Mantel-Haenszel 
test. Confidence intervals for the difference in proportions 
between treatment groups were calculated by Mantel- 
Haenszel methods. 
Because of gross departures from normality in the units 
of allogeneic blood required and the number of milliliters 
of allogeneic blood required, the null hypothesis of no 
treatment difference was tested by means of a two-way 
analysis of variance of ranked data, with the data ranked 
over all the centers. A standard two-way analysis of 
variance model was used for all other continuous vari- 
ables. The analysis of variance model included the effects 
of drug, center, and drug-by-center interaction. If no 
significant drug-by-center interaction was observed, the 
main effect's model was used. When a standard analysis of 
variance model was used, least square means for each 
treatment and 95% confidence intervals (CI) for the 
pairwise treatment differences were calculated. No confi- 
dence intervals were presented when the ranked data 
were analyzed because of difficulty in interpretation. In 
this case, however, the least square means reported were 
calculated with the use of the untransformed data. 
To investigate the effect of the patient's baseline char- 
acteristics on the probability of getting a transfusion, we 
pooled the data across treatment groups and analyzed 
them using a logistic regression model with age, height, 
weight, and red blood cell mass as independent variables. 
A term for center was always included in the model. Only 
age and red blood cell mass were identified as indepen- 
dent predictors. A final logistic regression model was run 
to test the hypothesis of no treatment effect after adjusting 
for center and for differences in age and preoperative r d 
blood cell mass. 
Safety was assessed through the frequency distribution 
of adverse vents reported by the site investigator. Adverse 
events were categorized by similar diagnosis. No clinical 
parameters were established for the diagnosis of adverse 
events. Renal dysfunction was categorically defined as acute 
renal failure, renal failure, renal function abnormality, and 
renal tubular necrosis. Myocardial dysfimction was categor- 
ically defined as congestive heart failure and heart failure or 
both. Adverse events affecting the cardiovascular system 
included atrial and ventricular arrhythmias, hypotension, 
myocardial infarction, heart failure, and congestive heart 
failure. The frequency distribution of adverse events, as 
defined by the investigators, was analyzed by means of either 
Fisher's exact est or a )(2 test. Fisher's exact ests were used 
if at least 25% of the cells had expected values less than five; 
otherwise, Xa tests were used. 
Results 
Population. There were no significant differences 
among the treatment groups in demographic har- 
acteristics, preoperative hemoglobin values, preop- 
erative prothrombin time and partial thromboplas- 
tin time, preoperative creatinine concentration, history 
of previous myocardial infarction, type of valvular 
lesion present, types of operative procedure per- 
formed, history of hypertension, preoperative l ft ven- 
tricular ejection fraction, and preoperative New York 
Heaa't Association functional class (Table I). 
The intraoperative course was similar for all 
groups, including total crossclamp time, duration of 
the operation, and total anesthesia time (Table II). 
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Table I. Demographic summary 
High-dose Low-dose 
aprotinin aprotinin Placebo 
No. of patients 65 62 64 
Age (yr) 59.8 -+ 3.1 59.2 -+ 3.2 60.0 _+ 3.1 
Men (%) 48 53 47 
White (%) 95 90 95 
Weight (kg) 71.8 -+ 3.9 72.0 -+ 4.1 72.5 _+ 4.0 
Hypertension (%) 46 29 36 
Pulmonary hypertension (%) 34 47 40 
MI history (%) 12 3 8 
NYHA class 2.6 - 0.01 2.7 -+ 0.01 2.7 - 0,01 
Baseline PT (mg/dl) 11.8 +_ 12.3 12.0 _+ 11.6 11.9 _+ 10.9 
BAseline PTT (mg/dl) 31.4 --- 6.3 31.4 -+ 6.8 29.6 + 6,3 
BAseline Hgb (mg/dl) 13.5 _+ 0.04 13.6 _+ 0.04 13.5 _+ 0,04 
Baseline creatinine (mg/dl) 1.10 +_ 0.02 1.12 _+ 0.02 1.10 +- 0.02 
Aortic stenosis (%) 52 34 43 
Aortic insufficiency (%) 34 34 30 
Mitral stenosis (%) 18 24 21 
Mitral insufficiency (%) 34 53 51 
For continuous variables, results are presented as mean +- standard 
deviation. MI, Myocardial infarction; NYHA, New York Heart Association; 
PT, prothrombin time; PTT, partial thromboplastin time; Hgb, hemoglo- 
bin. 
The total bypass time was significantly different 
between the low-dose aprotinin group and the pla- 
cebo group (CI: difference between low-dose apro- 
tinin and placebo, 2.9% to 25.7%; p = 0.014). 
Transfusion prevalence. Few patients partici- 
pated in autologous predonation programs. There 
was no difference between the treatment groups in 
the percentages of patients predonating their blood 
(high-dose aprotinin, 5%; low-dose aprotinin, 6%; 
placebo, 5%). 
Aprotinin, high-dose and low-dose, did not signif- 
icantly reduce the percentage of patients requiring 
allogeneic transfusions. The percentages of patients 
who required allogeneic red blood transfusions 
(packed red blood cells and whole blood) were 63% 
(41/65) in the high-dose aprotinin group, 52% (32/62) 
in the low-dose aprotinin group, and 48% (31/64) in 
the placebo group; none of the pairwise hypothesis 
tests reached statistical significance for the difference 
in proportions between the treatment groups (differ- 
ence between high-dose aprotinin and placebo, CI = 
-2.2% to 31.8%, p = 0.092; difference between low- 
dose aprotinin and placebo, CI = -11.6% to 20.8%, 
p = 0.592). Even when all patients who received study 
medication and were operated on were included (in- 
tent-to-treat nalysis), there was no statistically signif- 
icant difference in the percentage ofpatients receiving 
allogeneic blood transfusions between the aprotinin 
treatment groups and the placebo group (high-dose 
aprotinin group, 66% transfused; low-dose aprotinin 
group, 56% transfused; placebo, 53% transfused). The 
Table II. Intraoperative course 
High-dose Low-dose 
aprotinin aprotinin Placebo 
Total bypass time (rain) 
Total crossclamp time (rain) 
Total anesthesia time (lax) 
Duration of operation Oar) 
Aortic replacement orrepair (%) 
Mitral replacement (%) 
Mitral repair (%) 
Tricuspid or pulmonic 
replacement/repair (%)
Aortic and mitral 
repair/replacement (%)
Other combination (%) 
102.1 -+ 4.0 107.4 _+ 4.1 93.1 - 4.0 
64.5 -+ 3.1 67.3 -+ 3.2 59.7 -+ 3.2 
4.6+_0.1 4.5 _+ 0.1 4.3+0.1 
3.5 + 0.1 3.5 + 0.1 3.2 -- 0.1 
62 44 52 
15 29 23 
15 15 19 
3 0 0 
5 10 3 
0 3 3 
For continuous variables results are presented asmean +- standard error. 
confidence interval for the difference in proportions 
between the high-dose aprotinin group and the pla- 
cebo group was -3.0% to 29.3% (p = 0.113) and for 
low-dose aprotinin and placebo groups, -12.9% to 
17.8% (p = 0.763). 
There were no statistically significant differences 
among the treatment groups in the mean number of 
units of allogeneic blood transfused (given as 
mean ± standard error): red blood cells (high-dose 
aprotinin, 2.0 +_ 0.4 units; low-dose aprotinin, 1.9 _ 
0.4 units; placebo, 1.3 _+ 0.4 units), platelets (high- 
dose aprotinin, 2 ± 0.7 units; low-dose aprotinin, 
0.4 ± 0.7 units; placebo, 0.9 ± 0.7 units), fresh 
frozen plasma (high-dose aprotinin, 0.4 ± 0.2 units; 
low-dose aprotinin, 0.4 ___ 0.2 units; placebo, 0.5 ± 
0.2 units), or cryoprecipitate (high-dose aprotinin, 
0.2 ± 0.2 units; low-dose aprotinin, 0.2 ± 0.2 units; 
placebo, 0.3 ___ 0.2 units). 
The transfusion distribution in the high-dose 
aprotinin group was significantly different from 
those in the low-dose aprotinin and placebo groups. 
Forty-six percent of patients in the high-dose apro- 
tinin group received intraoperative transfusions 
compared with 37% in the low-dose aprotinin group 
and 23% in the placebo group (CI: difference be- 
tween high-close aprotinin and placebo, 7% to 39%, 
p = 0.006; difference between low-dose aprotinin 
and placebo, -0.9% to 30%,p = 0.073; Fig. 1). This 
difference among the treatment groups did not 
persist into the postoperative period. During the 
first 24 hours after the operation 15% of high-dose 
aprotinin group, 16% of the low-dose aprotinin 
group, and 28% of the placebo group received 
transfusions (CI: difference between high-dose 
aprotinin and placebo, -26% to 1%; difference 
between low-dose aprotinin and placebo, -25% to 
3%). The transfusion prevalences were similar for 
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Fig. 1. The intraoperative rate of transfusion for patients 
treated with high-dose aprotinin was significantly higher 
than the rate of transfusion for patients in the low-dose 
aprotinin and placebo treatment groups (p = 0.03). This 
difference did not continue into the postoperative p riod 
(p > 0.05). POD, Postoperative day. 
all groups during the interval from postoperative day 2 
through discharge, with 20% of the high-dose aproti- 
nin group, 19% of the low-dose aprotinin group, and 
19% of the placebo group requiring allogeneic blood 
(CI: difference between high-dose aprotinin and pla- 
cebo, -12% to 14%; difference between low-dose 
aprotinin and placebo, -12% to 14%). 
A difference xisted among the treatment groups 
when the number of units of blood was stratified. 
Eighteen percent of the high-dose aprotinin group 
received one unit of allogeneic blood whereas 3% of 
the low-dose aprotinin group and 9% of the placebo 
group received only one unit of allogeneic blood 
(p = 0.02). This difference did not persist when two 
or more units of allogeneic blood were transfused. 
Additionally, the use of allogeneic blood did not 
correlate with the mediastinal chest ube drainage in 
the high-dose aprotinin group (Fig. 2). 
The percentages of patients who required alloge- 
neic blood transfusions were also analyzed accord- 
ing to baseline characteristics including sex, age, and 
body weight (Table III). In each of these subcate- 
gories, as with the overall analysis, there was a trend 
toward an increased percentage of patients requir- 
ing allogeneic blood in the aprotinin groups. 
Red cell Mood volume. More patients in the 
high-dose aprotinin group than the other two treat- 
ment groups had preoperative red blood cell vol- 
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Fig. 2. Mediastinal drainage was not a predictor of the 
number of allogeneic red blood cells required in the 
high-dose aprotinin group. The different bars represent 
the number of units transfused. 
umes less than or equal to 1600 ml (high-dose 
aprotinin, 40%; low-dose aprotinin, 34%; placebo, 
31%). The 95% confidence interval for the differ- 
ence between the high-dose aprotinin group and the 
placebo group in the proportion of such patients 
ranged from -8% to 25% (p = 0.305), whereas the 
95% confidence interval for the difference between 
the low-dose aprotinin treatment group and the 
placebo group ranged from -13% to 17% (p -- 
0.794). Of those patients with a preoperative red 
blood cell volume less than or equal to 1600 ml, 
85%, 71%, and 60% of the patients received trans- 
fusions of allogeneic red blood cells in the high-dose 
aprotinin, low-dose aprotinin, and placebo groups, 
respectively (high-dose aprotinin vs placebo, p = 
0.913; low-dose aprotinin vs placebo, p = 0.732). 
Postoperative mediastinal shed blood. The post- 
operative thoracic drainage rate was statistically 
significantly less in the high-dose aprotinin (37 ml/ 
hr; p = 0.0001) and in the low-dose aprotinin (46 
ml/hr; p = 0.0001) treatment groups than in the 
placebo-treated patients (71 ml/hr) during the first 8 
hours after the operation. The total postoperative 
thoracic drainage was reduced by 33% in the high- 
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Table III. Proportion of patients requiring any 
allogenic blood, broken down by age, sex, and weight 
High-dose Low-dose 
aprotinin aprotinin Placebo 
Characteristic Subgroup (n = 65) (n = 62) (n = 64) 
Sex Male 
Female 
Age < 60 yr 
-> 60 yr 
Weight < 60 kg 
>- 60 kg 
15/31 (48%) 11/33 (33%) 10/30 (33%) 
26/34 (76%) 21/29 (72%) 21/34 (62%) 
12/29 (41%) 13/30 (43%) 10/30 (33%) 
29/36 (81%) 19/32 (59%) 21/34 (62%) 
15/18 (83%) 9/13 (69%) 9/11 (82%) 
26/47 (55%) 23/49 (47%) 22/53 (42%) 
dose aprotinin group (p -- 0.002) and by 26% in the 
low-dose aprotinin group (p = 0.017), as compared 
with the placebo group. In addition, there appears 
to be a trend toward a dose response to aprotinin in 
patients over the age of 59 years (high-dose aproti- 
nin vs placebo, p = 0.0001; low-dose aprotinin vs 
placebo, p = 0.0032). 
Treatment with other hemostatie drugs. The ad- 
ministration of therapeutic hemostatic agents, other 
than aprotinin, to control bleeding after cardiopul- 
monary bypass differed significantly among the 
treatment groups. The percentage of patients 
treated with epsilon-aminocaproic acid in the pla- 
cebo group was 6% (4/64), whereas no patients in 
the aprotinin groups were treated with epsilon- 
aminocaproic a id. This difference in the percentage 
of patients receiving epsilon-aminocaproic acid was 
significant for both aprotinin groups when com- 
pared with the placebo group (p = 0.05). Desmo- 
pressin therapy was given to 9% (6/65) of the 
high-dose aprotinin group, 8% (5/61) of the low- 
dose aprotinin group, and 19% (12/64) of the pla- 
cebo group (CI: difference between high-dose apro- 
tinin and placebo, -22% to 2%; difference between 
low-dose aprotinin and placebo, -22% to 1%). 
However, the exclusion of patients treated with 
epsilon-aminocaproic a id alone, desmopressin 
alone, or both, did not affect the difference in 
transfusion requirement between the aprotinin and 
placebo groups. 
Hemoglobin. The percentage change in hemoglo- 
bin value from the preoperative baseline value to 
postoperative day 7 was statistically significant for 
the high-dose aprotinin group compared with the 
placebo and low-dose aprotinin groups. The changes 
in hemoglobin from the baseline value to the post- 
operative value were a decrease of 2.46 gm/dl for the 
high-dose aprotinin group, 3.29 gm/dl for the low- 
dose aprotinin group, and 3.29 gm/dl for the placebo 
group (CI: difference between high-dose aprotinin 
and placebo, -1.43 to -0.23, p = 0.007; difference 
Table IV. Treatment of emergency events 
categorically defined as renal dysfunction 
Event 
High-dose Los-dose 
aprotinin aprotinin Placebo Overall 
(n= 71) (n = 70) (n=71)  p value 
Renal function abnormal 6 0 0 0.004 
Renal failure 1 4 0 0.049 
Renal tubular necrosis 1 0 0 1.000 
Acute kidney failure 0 1 0 0.330 
between high-dose aprotinin and low-dose aprotinin 
and placebo, -1.43 to -0.22, p = 0.008) as a result 
of the higher intraoperative transfusion rates and 
the reduction in postoperative shed mediastinal 
drainage in the aprotinin-treated groups. 
Safety. A total of 212 patients were eligible for 
the safety analysis: 71 in the high-dose aprotinin 
group, 70 in the low-dose aprotinin group, and 71 in 
the placebo group. 
The overall incidence rates for reported adverse 
events in the high-dose aprotinin group, the low- 
dose aprotinin group, and the placebo group were 
not significantly different (p = 0.838). Seventy-six 
percent of the high-dose aprotinin group, 73% of 
the low-dose aprotinin group, and 72% of the 
placebo group reported one or more adverse vents 
during the study. 
There were no statistically significant differences 
in the overall incidence rates of postoperative car- 
diovascular complications between the high-dose 
aprotinin group (61%), the low-dose aprotinin 
group (53%), and the placebo group (61%) when all 
reported events affecting the cardiovascular system 
were combined (p = 0.565). 
There were no differences in the frequency of 
thrombotic events in patients treated with aprotinin 
or placebo, including thrombosis (high-dose aproti- 
nin, 1%; low-dose aprotinin, 0%; placebo, 0%) and 
deep vein thrombosis (high-dose aprotinin, 1%; 
low-dose aprotinin, 0%; placebo, 0%). Myocardial 
infarctions were reported in four patients in the 
high-dose aprotinin group (6%), one patient in the 
low-dose aprotinin group (1%), and three patients 
in the placebo group (4%; p = 0.54). Three patients 
were reported to have cerebrovascular ccidents 
(one in each treatment group). One additional 
patient had a cerebral vascular accident (low-dose 
aprotinin) 31 days after discharge from the hospital. 
Five patients died during the study (high-dose 
aprotinin, n = 3; low-dose aprotinin, n =- 2). One 
patient in the low-dose aprotinin group died within 
1 week of receiving the study medication. The 
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Table V, Patients with renal dysfunction 
Baseline creatinine Peak creatinine 
Treatment ~'oup Status Study ID value (mg/dl) value (mg/dl) Days postop. 
High-dose Diabetes 1016 1.2 4.7 25 
Diabetes 102l 1.3 4.1 7 
Diabetes 5025 1.2 1.8 2 
No diabetes 1040 0.9 2.5 16 
No diabetes 3031 1.3 2.4 3 
No diabetes 3038 1.6 2.3 2 
No diabetes 3041 1.3 3.4 4 
No diabetes 5040 0.9 4.3 7 
Low-dose No diabetes 1002 1.8 3.7 7 
No diabetes 1008 0.8 4.9 5 
No diabetes 1035 1.3 3.2 36 
No diabetes 2028 1.4 4.1 2 
No diabetes 3028 1.4 8.1 5 
remainder of the patients died more than 1 month 
after receiving the study medication. One additional 
patient in the low-dose aprotinin group died during 
a hospital readmission 31 days after discharge. 
Renal dysfunction. Renal dysfunction was signif- 
icantly more prevalent in the high-dose (11%) and 
low-dose (7%) aprotinin groups than in the placebo 
group (0%; p = 0.008). Table IV contains the 
breakdown of the reported renal treatment emer- 
gency events by study group. 
The patients did not require dialysis, except for 
three (high-dose aprotinin, n = 1; low-dose aproti- 
nin, n = 2) categorized as having renal dysfunction. 
Two (low-dose aprotinin) of the three patients who 
had renal failure necessitating dialysis died (sepsis 
and cardiogenic shock) without their renal dysfunc- 
tion being resolved. In the third patient who re- 
quired dialysis, the renal failure had resolved by the 
time of discharge. 
To investigate whether certain baseline character- 
istics would correlate with the prevalence of renal 
dysfunction, we calculated by-treatment rates for 
the following factors: weight (->85 kg vs <85 kg), 
sex, age (->60 years vs <60 years), presence of 
diabetes mellitus, hypertension, congestive heart 
failure, aminoglycoside treatment, preoperative an- 
giotensin-converting enzyme inhibitor, and transfu- 
sion of allogeneic blood (->3 units vs <3 units). 
Sixteen percent (3/18) of the patients with diabetes 
mellitus had renal dysfunction in comparison with 
5% (10/194) of those without diabetes (Table V). 
All three of the patients with diabetes in whom renal 
dysfunction developed were randomized to the high- 
dose aprotinin group. However, interpretation of 
these data must take into account that the study 
comprised few patients with diabetes mellitus. Other 
factors associated with an increased incidence of 
renal events were age 60 years or older, a baseline 
diagnosis of congestive heart failure, transfusion of 
three or more units of allogeneic blood, aminogly- 
coside treatment, and preoperative treatment with 
angiotensin-converting e zyme inhibitors. No other 
trends in the incidence of renal dysfunction by 
baseline characteristics were observed. 
Elevated baseline serum creatinine values (de- 
fined as a serum creatinine at any study site that 
exceeded the upper limit of the normal range at that 
site's laboratory) did not appear to predispose Pa- 
tients to renal dysfunction. In patients with an 
elevated baseline creatinine value, none of the pa- 
tients treated with high-dose aprotinin, 17% of 
those treated with low-dose aprotinin, and none of 
those treated with placebo had postoperative r nal 
dysfunction. The frequency of renal dysfunction in 
patients without an elevated baseline creatinine 
value was 12% in the high-dose aprotinin group, 6% 
in the low-dose aprotinin group, and 0% in the 
placebo group. 
In view of the increased incidence of renal dys- 
function in the high-dose aprotinin group, the inci- 
dence of a clinically significant increase in serum 
creatinine from the baseline preoperative sample to 
the postoperative samples was examined. Increases 
in creatinine concentration of 0.5 mg/dl or greater 
occurred in 30% (21/71) of the high-dose aprotinin 
group, 14% (10/70) of the low-dose aprotinin group, 
and 8% (6/71) of the placebo group (p = 0.003). 
This difference between the treatment groups did 
not persist when an increase in the serum creatinine 
of greater than 2.0 mg/dl was considered (Fig. 3). 
Additional operations. Patients returned to the 
operating room for a variety of procedures including 
sternal ddbridement (n = 1), wound closure and 
intraaortic balloon pump removal (n = 1), bleeding 
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Fig. 3. Changes in serum creatinine concentration of 
>-0.5 mg/dl occurred significantly more often in the apro- 
tinin-treated group (p = 0.003). This difference did not 
persist for a change in creatinine of >2 mg/dl. Creat, 
Creatinine. 
from a surgically localized anatomic site (n = 10), 
heart transplantation ( = 1), diffuse bleeding (n = 
1), perivalvular leak (n = 1), and insertion of a 
pacemaker (n = 2), Seven percent of the placebo 
group required an additional operation, as did 1% 
of the high-dose aprotinin and low-dose aprotinin 
treatment groups (p = 0.043 for high- and low-dose 
aprotinin groups vs placebo). 
Discussion and conclusions 
According to previous reports, aprotinin reduces 
bleeding, decreases transfusion requirements, and is 
relatively safe when compared with other interven- 
tions used routinely in patients having cardiac oper- 
ations. ~3 In the current study aprotinin was not 
effective in decreasing the transfusion requirements, 
probably because of the nature of the operations: 
primary sternotomy for valve operations, no leg 
incision, and short cardiopulmonary bypass and 
crossclamp times. Although there was no statisti- 
cally significant difference in the transfusion rates 
for aprotinin-treated groups in comparison with the 
placebo group, the higher transfusion rate and 
smaller preoperative red cell volume seen in the 
high-dose aprotinin treatment group may have 
achieved statistical significance if the sample size 
had been larger. This would have supported the 
increased transfusion rate resulting from smaller 
preoperative r d cell volumes. 
The mechanism by which aprotinin reduces blood 
loss in patients undergoing cardiac operations ap- 
pears to be through its ability to preserve normal 
coagulation. Aprotinin has been shown to inhibit 
contact activation, preserve the integrity Of platelet 
receptors, 15inhibit fibrinolysis by binding reversibly 
to plasmin, 6 inhibit various enzymes along the in- 
trinsic clotting pathway, 16 and block the inflamma- 
tory response by inhibiting the activation of prekal- 
likrein. 17 The use of a nonkallikrein-inhibiting 
aprotinin dose, the low-dose aprotinin regimen, in 
this study calls into question the latter mechanism of 
action, because a dose-dependent reduction in me- 
diastinal drainage was seen. 
A significant number of patients in the high-dose 
aprotinin group had a postoperative increase in 
serum creatinine of ->0.5 mg/dl. The selection of a 
0.5 mg/dl change was based on the data previously 
reported in the literature. TMDespite the presence of 
statistically significant increases in the creatinine 
concentration, the development of postoperative 
renal dysfunction did not appear to have long-term 
clinical implications except in the three patients who 
required dialysis. Although the number of patients 
with diabetes participating in this study was small 
(n = 18), all of those who had renal failure were in 
the high-dose aprotinin group (3/8); renal failure did 
not develop in any of the patients with diabetes in 
the other two groups (low-dose aprotinin, 0/6; pla- 
cebo, 0/4). This finding is consistent with the report 
by Lemmer and associates, ~9in which patients with 
diabetes who were treated with aprotinin had in- 
creases in serum creatinine levels (0.5 gm/dl or 
greater) more often than those randomized to the 
placebo group. Because the number of patients with 
diabetes in the present study was small, the finding 
requires further characterization with the establish- 
ment of prospective definitions of renal dysfunction. 
It is not an unexpected finding, however, consider- 
ing the mechanism by which the kidney handles 
aprotinin. The proximal tubular epithelial cells take 
up small proteins like aprotinin and insulin to 
recycle the amino acids. With large protein loads, 
such as with a standard high-dose aprotinin treat- 
ment regimen, this system might be overwhelme& 
Proximal tubular cells swell and mechanical effects 
on filtrate flow have been observed, As the cells 
process the protein over a 12- to 24-hour period, the 
mechanical effects reverse. 19 
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Concern has been raised about the potential 
increased risk of thrombotic complications with 
aprotinin therapy in patients having cardiac oper- 
ations. 2° In this study, the rates of thrombotic 
complications did not differ among treatment 
groups. 
The lack of efficacy may have been influenced by 
the lower red cell mass seen in the high-dose 
aprotinin group. Because there were no differences 
in the baseline hemoglobin values, the need for only 
one unit of allogeneic blood suggests that the trans- 
fusions in the high-dose aprotinin group were for 
inadequate red cell mass, not blood loss. The lack of 
correlation between mediastinal drainage and red 
cell transfusion in the high-dose aprotinin group 
also supports the conclusion that many transfusions 
in this group were the result of preexisting low red 
cell mass. In addition, the relative polycythemia seen 
in the high-dose group at discharge in comparison 
with the low-dose aprotinin and placebo groups 
suggests excessive transfusion. It is possible that 
anticipatory transfusion may be responsible for the 
higher transfusion rates seen in the high-dose apro- 
tinin group which, when combined with the reduc- 
tion in postoperative blood loss, translated into a 
significantly higher hematocrit value on discharge. 
This fact implies that, for whatever reason, the 
high-dose aprotinin group received excessive trans- 
fusions despite the fact that they bled less. This 
observation supports the need to include preopera- 
tive red cell mass in the randomization schemes in 
future studies of blood-sparing agents. It also sug- 
gests that using the number of patients receiving 
transfusions as a study end point is confounded by 
the problem of hemodilution, not just bleeding. 
Nonetheless, the data suggest that aprotinin 
should be used cautiously in patients with preop- 
erative renal dysfunction or diabetes until further 
controlled studies can be conducted in these 
populations. 
We recognize Dr. Alan Zaslavsky, Dr. Lawrence 
Schwartz, and Dr. Andrea Nadel for their help with the 
statistical analysis and the late Dr. Edwin Land and Mrs. 
Edwin Land for their kindness and moral support 
throughout he conduct of this study. 
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